泽璟制药(688266) - 2025 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of RMB 81,273.36 million, representing a year-on-year increase of 52.50%[5] - The net profit attributable to shareholders of the parent company was a loss of RMB 16,069.72 million, with a year-on-year increase in losses[5] - The weighted average return on net assets was -13.76%, an increase in losses by 4.34 percentage points compared to the previous year[5] - Total assets at the end of the reporting period were RMB 297,143.46 million, while equity attributable to shareholders of the parent company was RMB 108,269.72 million[5] - The net asset per share attributable to shareholders of the parent company decreased to RMB 4.09, down 13.71% from the previous year[4] Product Development and Market Expansion - The company successfully launched Jikaxitini tablets and expanded market coverage, contributing to revenue growth[5] - Recombinant human thrombin was officially included in the national medical insurance catalog, leading to a significant increase in sales[5] - R&D expenses increased year-on-year due to the varying stages of new drug development projects[5] - The company plans to continue its efforts in new drug research and market expansion[5] Financial Data and Risk Disclosure - The company emphasizes the preliminary nature of the financial data, which has not been audited, and warns investors of potential risks[7][8]